Subscribe to Updates in Healthcare

RSS By Email

RSS By RSS

Add to Google Reader or Homepage

Subscribe in Bloglines


The Expertise Imperative and Compliance Technology
Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.Learn more about GLG's Compliance Framework


This page may include content provided by Council Members, your access to which is subject to the Terms of Use.
Find Out More

GLG News by Sutent Prescribers for RCC: Oncologists (US)

Articles with lock require a subscription to GLG News | Request a free trial
June 9, 2008
Diabetes: Let's avoid pseudoscience and start over.....
Analysis of: Tight Rein on Blood Sugar Has No Heart Benefit | www.nytimes.com
Author: GLG Expert Contributor
Tight Glucose control in type 2 diabetes mellitus did not result in improved survival and possibly had a negative impact.
June 4, 2008
Trovax(R) Sanofi-Aventis and Oxford Biomedica: Interesting but.....
Analysis of: Sanofi-Aventis and Oxford Biomedica report encouraging Trovax(R) phase II trial results in Metastatic Renal Cancer | www.pipelinereview.com
Author: GLG Expert Contributor
This immunotherapeutic agent in association with interleukin 2 or interferon may be effective in renal cell carcinoma (RCC). To be tested in a phase III trial (against what??)
June 4, 2008
ASA404 in a phase III trial in lung cancer?? "A crap shoot?"
Analysis of: Positive data on Antisoma’s ASA404 presented at ASCO | www.pipelinereview.com
Author: GLG Expert Contributor
That appears to be a well contructed phase III trial adds ASA404 or a placebo to Taxol/Carboplatin. Nothing exotic, endpoints are overall survival (OS) as well as OS in Squams and non Squams.
June 2, 2008
A New Algorithm Will be Needed to Calculate Market Sharee
Analysis of: Genetic Research May Help Pick Patients' Best Cancer Drugs | online.wsj.com
Author: GLG Expert Contributor
Genetic profiling will tell us who should or should not receive particular anti neoplastic agents. This is "personalized" therapy that has been predicted x years.
June 2, 2008
ImClone: One study shot down. The other??
Analysis of: Drug Brings ImClone in From Cold | online.wsj.com
Author: GLG Expert Contributor
Well we know that the lung cancer trial  http://online.wsj.com/article/SB121227163771635641.html?mod=2_1566_topbox was a bust so far. What other "good news" do we await
June 2, 2008
Erbitux (ImClone):1 month and <10% additional survival in lung cancer. Not very impressive!
Analysis of: Erbitux Slightly Boosts Survival in Cancer Study | online.wsj.com
Author: GLG Expert Contributor
Basically?? It's a bust until we see subset analysis. It is possible adenocarcinomas as well as non smokers will show better survival
May 27, 2008
Revlimid (Celgene) in CLL- not a bad addition in our therapeutic algorithm
Analysis of: Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia | bloodjournal.hematologylibrary.org
Author: GLG Expert Contributor
Revlimid has activity in Chronic Lymphatic Leukemia (CLL) in addition to myeloma and myelodysplasia.
May 27, 2008
So much for non-invasive surgery in prostate cancer
Analysis of: Mixed Outcomes in Laparoscopy for Prostates | www.nytimes.com
Author: GLG Expert Contributor
Higher recurrance rate???!!!
May 27, 2008
Genentech, Schering-Plough,,Avant Immunotherapeutics. & Pfizer all helping with "brain cancer" therapy.
Analysis of: Hints of Progress in Drugs Treating Brain Cancer | www.nytimes.com
Author: GLG Expert Contributor
     While no slam dunk cures are noted, drugs such as Avastin (Genentech), Temodar (Schering-Plough) &  Avant/Pfizer  vaccines  are making an impact on  "Brain Cancer"  survival.
Donald FlemingMay 23, 2008
Erbitux and Lung cancer
Analysis of: Phase II trial of gemcitabine, docetaxel, and cetuximab in advanced non-small-cell lung cancer (NSCLC). | www.abstract.asco.org
Author: Donald Fleming, Division Head of Hematology and Oncology, Davis Health System, Inc.
Erbitux has had a few high level trials in Non small lung cancer So far there does not appear to be a contributuion to chemotherapy Maybe we are going about it the wrong way

Previous Page : 1 2 3 4 5 6 7 8 9 10 11 12 13 14 Next41 to 50 of 466

More GLG News in
Healthcare

Most Popular:
Source Article | Expert Analyses
 

GLG News: What Experts Think Is Important





Analytics


Generated at 2008-08-29T21:45:17.707